TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MDMA-Assisted Psychotherapy in People With Posttraumatic Stress Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Have current PTSD (within the past 6 months) in response to crime victimization, including childhood sexual or physical abuse, or meet criteria for PTSD in response to combat;~* Have a CAPS score showing moderate to severe PTSD symptoms;~* They must either:~  1. Have had at least one unsuccessful attempt at treatment for PTSD with a SSRI and psychotherapy;~ 2. Be a veteran with PTSD symptoms that have endured for no less than one year but no more than five years~* Be at least 18 years old;~* Must be generally healthy;~* Willing to remain overnight at the study site;~* Agree to have transportation home the morning after experimental sessions;~* Are willing to be contacted via telephone for all necessary telephone contacts;~* Must have a negative pregnancy test if able to bear children and agree to use an effective form of birth control;~* Are proficient in reading English;~Exclusion Criteria:~* Are pregnant or nursing, or are able to bear children and are not practicing an effective means of birth control;~* Weigh less than 50 kg or more than 105 kg;~* Are unable to give adequate informed consent;~* Prior use of Ecstasy (illicit drug preparations purported to contain MDMA) more than 5 times or at any time within the previous 6 months;~* Have a history of certain excluded medical disorders.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- MDMA-assisted therapy (125 mg) (Type: EXPERIMENTAL): Participants will receive an initial dose of 125 mg midomafetamine HCl orally followed 2 to 2.5 hours later by a second dose of 62.5 mg midomafetamine HCl during two 8-hour long blinded therapy sessions.
- Placebo with therapy (Type: PLACEBO_COMPARATOR): Participants will receive an initial dose of 125 mg placebo orally followed 2 to 2.5 hours later by a second dose of 62.5 mg placebo during two 8-hour long blinded therapy sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome (DES)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Be male or female of any race, at least 18 years of age~* Have provided written informed consent~* Have a reported history of dry eye syndrome~* Have a history of use or desire to use eye drops for dry eye~Exclusion Criteria:~* Have any clinically significant eye findings that require therapeutic treatment or may interfere with study parameters~* Have previously had LASIK surgery within the last 12 months~* Have used Restasis® within 30 days of Visit 1~* Be a woman who is pregnant, nursing or planning a pregnancy~* Be unwilling to submit a urine pregnancy test if of childbearing potential~* Have a known allergy and/or sensitivity to the test article or its components, including the preservative benzalkonium chloride~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days of Visit 1~* Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low Dose SkQ1 (Type: EXPERIMENTAL): Drug: Low Dose 0.155µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
- High Dose SkQ1 (Type: EXPERIMENTAL): Drug: High Dose 1.55µg/mL SkQ1 ophthalmic solution administered twice daily for 28 days
- Placebo (vehicle) (Type: PLACEBO_COMPARATOR): Drug: Placebo (vehicle) ophthalmic solution administered twice daily for 28 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Supplementation of Marginally Low Birth Weight Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Marginally low birth weight (2000-2500 g)~* Healthy at inclusion(6 weeks of age)~* No previous blood transfusion~* No previous iron supplementation~Exclusion Criteria:~* Anemia at inclusion

- Gender: ALL
- Minimum Age: 39 Days
- Maximum Age: 45 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): 1 mg/kg/day from age 6 weeks to 6 months
- 3 (Type: EXPERIMENTAL): 2 mg/kg/day from age 6 weeks to 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Immunogenicity and Safety of GlaxoSmithKline Biologicals' HPV Vaccine in Young Males.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* A male between, and including, 10 and 18 years of age at the time of the first vaccination.~* Written informed consent obtained from the subject prior to enrolment~* For subjects below the legal age of consent, a written informed consent must be obtained from the subject's parent/guardian. In addition, a written informed assent must be obtained from the subject.~* Healthy subjects as established by medical history and clinical examination before entering into the study.~* Free of obvious health problems as established by medical history and clinical examination before entering into the study.~Exclusion criteria:~* Previous vaccination against Human Papillomavirus (HPV).~* Previous vaccination against Hepatitis B, known clinical history of Hepatitis B infection.~* Cancer or autoimmune disease under treatment.

- Gender: MALE
- Minimum Age: 10 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Cervarix Group (Type: EXPERIMENTAL): Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Cervarix™ (HPV-16/18 L1 VLP AS04) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.
- Engerix-B Group (Type: ACTIVE_COMPARATOR): Healthy male subjects between and including 10 to 18 years of age at the time of the first vaccination, who were administered 3 doses of Engerix-B™ (HBV) vaccine, intramuscularly into the deltoid region of the non-dominant arm, according to a 0, 1 and 6-month schedule. The subjects were followed up for 7 months after the first dose and an additional telephone contact was foreseen at Month 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Compare D961H 20 mg Bid and 20 mg qd in Patients With Refractory Reflux Esophagitis (Inflammation of Lower Esophagus)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Provision of informed consent prior to any study specific procedures.~2. Patients with RE classified into LA classification Grade A, B, C or D by Endoscopy despite of at least 8-week treatment using standard doses of PPIs.~3. Patients must fulfill at least one of the following criteria such as (i) RE with LA grade C/D at Endoscopy on visit 1 and/or history of RE with LA grade C/D, (ii) RE was diagnosed more than 1 year before visit 1.~4. Patients who are able to complete the Patient Diary~Exclusion Criteria:~1. Male or female aged less than 20 years at the time of informed consent.~2. Patients with current evidence of the gastrointestinal diseases/conditions such as esophageal stricture to interfere with the evaluation of the study etc~3. Gastric or duodenal ulcer verified by Endoscopy within 12 weeks before randomisation.~4. Previous esophageal, gastric or duodenal surgery except simple closure of perforated ulcer, simple endoscopic treatment with simple operation etc~5. Current or historical evidence (within 12 weeks prior to randomisation) of the diseases/conditions as judged to interfere with the evaluation of the study.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- D961H 20mg twice daily (Type: EXPERIMENTAL): Double-blinded
- D961H 20mg once daily (Type: ACTIVE_COMPARATOR): Double-blinded

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HCV Related Hepatocellular Carcinoma Recurrence After Directly Acting Antivirals: A Randomized Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child-Pugh A and B subjects with hepatitis C related \< 5 cm single or up to 3 hepatocellular carcinomas without any vascular or extrahepatic involvement~Exclusion Criteria:~* Those with positive HBsAg, history of alcohol consumption, patients with other known causes of chronic liver disease, patients who have received previous DAAs for HCV and patients who have received previous locoregional treatment for HCC will be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- DAAs group (Type: ACTIVE_COMPARATOR): Those with complete HCC ablation who will start sofosbuvir / velpatasvir aiming to eradicate HCV.
- Postponed DAAs group (Type: ACTIVE_COMPARATOR): Those who will not start DAAs within the 12 months follow up from HCC ablation procedure. Patients of this group will receive DAAs provided that there is no HCC recurrence after the end of 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has completed a colonoscopy according to the American Gastroenterological Association (AGA) criteria, with no clinically significant findings~* Patient has no clinically significant findings on a physical examination and clinical laboratory tests~* Patient meets protocol criteria for diagnosis of IBS-C~* Patient demonstrates continued IBS-C through Pretreatment Period~* Patient maintains a minimum level of compliance with daily diary~Exclusion Criteria:~* Patient has history of loose or watery stools~* Patient has symptoms of or been diagnosed with a medical condition that may contribute to abdominal pain~* Patient has a structural abnormality of the gastrointestinal (GI) tract or a disease or condition that can affect GI motility~* Patient has any protocol-excluded or clinically significant medical or surgical history that could confound the study assessments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 30 μg linaclotide DR1 and placebo (Type: EXPERIMENTAL): None
- 100 μg linaclotide DR1 and placebo (Type: EXPERIMENTAL): None
- 300 μg linaclotide DR1 and placebo (Type: EXPERIMENTAL): None
- 30 μg linaclotide DR2 and placebo (Type: EXPERIMENTAL): None
- 100 μg linaclotide DR2 and placebo (Type: EXPERIMENTAL): None
- 300 μg linaclotide DR2 and placebo (Type: EXPERIMENTAL): None
- 290 μg linaclotide IR and placebo (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females and males 18 years of age and older with uncomplicated, symptomatic malaria as as indicated by the presence of both of the following:~* Blood smears positive for Plasmodium falciparum asexual parasitemia between 1000 -100,000 parasites~* Documented fever (38.5 C/101.3 F rectal or tympanic; 37.5 C/99.5 F axillary or 38 C/100.4 F oral) or history of fever (as reported by subject) within the prior 24 hours.~Exclusion Criteria:~* Severe or complicated malaria.~* Pregnant or breast-feeding women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None
- 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Magnesium Sulphate in Perinatal Asphyxia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Babies eligible for the study were:~  1. Term or post term~ 2. Less than 6 hours of age and had~ 3. severe perinatal asphyxia as manifested by any three of the following criteria.~     * History of fetal distress (late deceleration, Loss of beat to beat variability, fetal bradycardia, meconium stained amniotic fluid)~    * Need for immediate neonatal ventilation with bag and mask or through endotracheal intubation for 2 minutes or more after delivery~    * A 5-minute Apgar score of \< 6~    * Base deficit 15 mEq/L in cord blood or admission arterial or cord blood pH 4.Moderate to severe encephalopathy~Exclusion Criteria:~* Patients with severe IUGR~* Any condition unrelated to asphyxia~* Maternal prenatal magnesium administration~* Metabolic disorder~* Chromosomal anomalies; and~* Congenital malformations were excluded from the study

- Gender: ALL
- Minimum Age: 1 Hour
- Maximum Age: 6 Hours
- Healthy Volunteers: f

Study Arms:
- Magnesium sulphate, neurological outcome (Type: ACTIVE_COMPARATOR): Magnesium sulphate 250mg/kg after every 24 hours starting within 6 hours from birth
- Placebo (Type: PLACEBO_COMPARATOR): Placebo every 24 hours for 3 doses starting from 6 hours after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Resveratrol's Effects in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes mellitus (DM)~* Controlled blood sugar \[fasting blood sugar (FBS) \<130mg/dl and glycosylated hemoglobin (A1C)\<7%~* Urine albumin \>20mg/lit in two separate occasions during the last 3 months period~* Serum creatinin \< or = 2mg/dl~Exclusion Criteria:~* Pregnancy~* Lactation~* Alcoholism~* Liver failure (acute or chronic)~* Renal failure: serum creatinin \>2mg/dl~* Glomerulonephritis~* Uncontrolled hypertension~* Congestive heart failure~* Prostate disease~* Malignancy~* Bilateral renal artery stenosis~* Any systemic disease other than DM~* Any infection or rheumatologic disorder~* Use of warfarin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Resveratrol (Type: EXPERIMENTAL): Resveratrol + Losartan
- Placebo (Type: PLACEBO_COMPARATOR): Placebo + Losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 6 to 17 years old~* Subjects with stable neurological disease and neurogenic detrusor overactivity~* Subjects using clean intermittent catheterization may participate~Exclusion Criteria:~* Concomitant medications which may increase the risk to subjects or confound study results~* Other medical conditions which may increase the risk to subjects or confound study results~* Contraindications to the use of fesoterodine or oxybutynin

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Fesoterodine PR 4 mg (Type: EXPERIMENTAL): Fesoterodine PR 4 mg for 12 weeks in active comparator period, followed by 12 weeks in safety extension period
- Fesoterodine PR 8 mg (Type: EXPERIMENTAL): Fesoterodine 8 mg for first week followed by 11 weeks at 8 mg in active control period, followed by 12 weeks in safety extension period.
- Oxybutynin (Type: ACTIVE_COMPARATOR): Oxybutynin
- Fesoterodine BIC 2 mg (Type: EXPERIMENTAL): Fesoterodine BIC 2 mg for 12 weeks in efficicay period, followed by 12 weeks in safety extension period.
- Fesoterodine BIC 4 mg (Type: EXPERIMENTAL): Fesoterodine BIC 4 mg for first week followed by 11 weeks at 8 mg in the efficacy period, followed by 12 weeks in safety extension period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Endoscopic Variceal Ligation (EVL) With Propranolol in Non Cirrhotic Portal Hypertension (NCPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Non Cirrhotic Portal Hypertension (NCPH) presenting to our Liver Diseases Follow-up Clinic with history of hemetemesis and/or malena within the past 6 weeks and proven to have esophageal varices as the bleeding source on upper GI endoscopy~Exclusion Criteria:~* A history of surgery for portal hypertension~* Patients already on a EST, EVL, or glue injection program before presenting to our hospital~* Patients already on beta blockers for primary prophylaxis of variceal bleed~* Severe cardiopulmonary or renal disease~* Bradycardia (basal heart rate, \<50 beats per minute \[bpm\]) or complete heart block~* A history of severe side effects or contraindications to β- blockers, like bronchial asthma, diabetes mellitus, heart failure, peripheral vascular disease, prostatic hypertrophy, or arterial hypotension (systolic blood pressure \<90 mm Hg)~* Refusal to give informed written consent to participate in the trial~* Patients bleeding from gastric varices or Portal Hypertensive Gastropathy (PHG).~* Patients who had a failure of primary hemostasis during acute bleed were also excluded.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Endoscopic Variceal Ligation (Type: ACTIVE_COMPARATOR): endoscopic therapy to obliterate varices
- Propranolol (Type: ACTIVE_COMPARATOR): drugs to decrease portal pressure

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: WelChol® With Metformin in Treating Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18-75 years, inclusive~* Diagnosed with type 2 diabetes~* Hemoglobin (HbA1c) between 7.5% to 9.5%~* Prescribed an ADA accepted diet~* Receiving stable dose of metformin alone or in combination with other oral anti-diabetic medications for 90 days before Visit 1~Exclusion Criteria:~* History of type 1 diabetes or ketoacidosis~* History of chronic (more than 2 months) insulin therapy or the initiation of insulin for chronic treatment~* History of pancreatitis~* Uncontrolled hypertension~* Recent severe cardiovascular disease~* Allergy or toxic response to colesevelam or any of its components~* Body mass index (BMI) \>45 kg/m2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete